Ask a Fool: What Will Belviq's Launch Do for Arena?

In the following video, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who writes, "How do you think the initial sales of Arena Pharmaceuticals' (NASDAQ: ARNA  ) Belviq will be?"

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (5) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 27, 2013, at 1:19 AM, Foreeverlong wrote:

    Serious investors should ignore this piece. Max clearly has no idea what he is talking about. The sales of Qsymia have nothing to do with the sales prospects of Belviq. He says that the safety profiles of the two drugs are essentially the same....wrong! Belviq did not receive a REMS from the FDA, while Qsymia did. The sales pipeline of Qsymia was severely limited by the FDA , and the pipeline for Belviq was not. Belviq has a major BP partner and related sales force, Qsymia had neither. Belviq may be equally as good for Diabetes II control and treatment as weight reduction.

  • Report this Comment On June 27, 2013, at 1:36 AM, nobsperiod wrote:

    What short hedgefunds are you guys catering to?

    Leave ARENA ALONE>>>>>>>>>>

  • Report this Comment On June 27, 2013, at 8:20 AM, adumfraudstain wrote:

    Max and Brian- Only complete fools putting out repeated misinforming scam blogs on Belviq, and just about every US hedge fund are taking a terrible beating short ARNA since below $3 while pumping VVUS to $30+. Keep up the great work losers next time do your homework better.

  • Report this Comment On June 27, 2013, at 9:27 AM, bmc007 wrote:

    When I want to know what the hedge funds, MM (that's market manipulators), vested interests, etc. are thinking, I read (foolish) articles on this site. There can be no other reason because all of their (hit) pieces contain so much misinformation it's laughable!

  • Report this Comment On June 27, 2013, at 8:50 PM, chrispycrunch wrote:

    I have an $11-12 1-year target price on Arena. I've been following this company since after its breakout.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2511727, ~/Articles/ArticleHandler.aspx, 10/1/2016 1:27:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
ARNA $1.75 Down +0.00 +0.00%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $1.14 Up +0.01 +0.88%
VIVUS CAPS Rating: **